Venture Capital Deals and Investments
  • All Technology
  • AI
  • Autonomy
  • B2B Growth
  • Big Data
  • BioTech
  • ClimateTech
  • Consumer Tech
  • Crypto
  • Cybersecurity
  • DevOps
  • Digital Marketing
  • Ecommerce
  • EdTech
  • Enterprise
  • FinTech
  • GovTech
  • Hardware
  • HealthTech
  • HRTech
  • LegalTech
  • Nanotech
  • PropTech
  • Quantum
  • Robotics
  • SaaS
  • SpaceTech
AllNewsDealsSocialBlogsVideosPodcastsDigests

Venture Capital Pulse

EMAIL DIGESTS

Daily

Every morning

Weekly

Sunday recap

NewsDealsSocialBlogsVideosPodcasts
Lifordi Immunotherapeutics Secures Strategic Investment From Sanofi Ventures, Raising Total to $112M
CorporateVenture Capital

Lifordi Immunotherapeutics Secures Strategic Investment From Sanofi Ventures, Raising Total to $112M

•November 18, 2025
•Nov 18, 2025
0

Participants

Lifordi

Lifordi

company

Atlas Venture

Atlas Venture

investor

Sanofi Ventures

Sanofi Ventures

investor

ARCH Venture Partners

ARCH Venture Partners

investor

5amventures

5amventures

investor

Why It Matters

The funding validates the promise of ADC‑based therapies for autoimmune diseases and accelerates Lifordi’s progression toward Phase 2, making it a compelling partner for large pharma. It also gives Sanofi early exposure to a novel drug‑delivery platform that could broaden its immunology pipeline.

Deal Summary

Lifordi Immunotherapeutics announced a new strategic investment from Sanofi Ventures alongside continued support from ARCH Ventures, 5AM Ventures and Atlas Venture. The funding brings the company's total capital raised to $112 million and will back its Phase 1 ADC trial for rheumatoid arthritis. Sanofi Ventures’ principal will join Lifordi’s board as an observer.

0

Comments

Want to join the conversation?

Loading comments...